215 related articles for article (PubMed ID: 12911593)
1. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII.
Reding MT; Okita DK; Diethelm-Okita BM; Anderson TA; Conti-Fine BM
J Thromb Haemost; 2003 Aug; 1(8):1777-84. PubMed ID: 12911593
[TBL] [Abstract][Full Text] [Related]
2. Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII.
Reding MT; Okita DK; Diethelm-Okita BM; Anderson TA; Conti-Fine BM
J Thromb Haemost; 2004 Aug; 2(8):1385-94. PubMed ID: 15304045
[TBL] [Abstract][Full Text] [Related]
3. T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects.
Hu GL; Okita DK; Conti-Fine BM
J Thromb Haemost; 2004 Nov; 2(11):1908-17. PubMed ID: 15550021
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects.
Reding MT; Wu H; Krampf M; Okita DK; Diethelm-Okita BM; Christie BA; Key NS; Conti-Fine BM
Thromb Haemost; 2000 Oct; 84(4):643-52. PubMed ID: 11057864
[TBL] [Abstract][Full Text] [Related]
5. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
[TBL] [Abstract][Full Text] [Related]
6. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide.
James EA; Kwok WW; Ettinger RA; Thompson AR; Pratt KP
J Thromb Haemost; 2007 Dec; 5(12):2399-407. PubMed ID: 18034765
[TBL] [Abstract][Full Text] [Related]
7. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.
Pratt KP; Qian J; Ellaban E; Okita DK; Diethelm-Okita BM; Conti-Fine B; Scott DW
Thromb Haemost; 2004 Sep; 92(3):522-8. PubMed ID: 15351848
[TBL] [Abstract][Full Text] [Related]
8. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.
Jones TD; Phillips WJ; Smith BJ; Bamford CA; Nayee PD; Baglin TP; Gaston JS; Baker MP
J Thromb Haemost; 2005 May; 3(5):991-1000. PubMed ID: 15869596
[TBL] [Abstract][Full Text] [Related]
9. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans.
Hu GL; Okita DK; Diethelm-Okita BM; Conti-Fine BM
J Thromb Haemost; 2003 Oct; 1(10):2159-66. PubMed ID: 14521599
[TBL] [Abstract][Full Text] [Related]
10. FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.
Ettinger RA; Liberman JA; Gunasekera D; Puranik K; James EA; Thompson AR; Pratt KP
Blood Adv; 2018 Feb; 2(4):309-322. PubMed ID: 29444872
[TBL] [Abstract][Full Text] [Related]
11. Hemophilia A subjects with an intron-22 gene inversion mutation show CD4
Gunasekera D; Vir P; Karim AF; Ragni MV; Pratt KP
Front Immunol; 2023; 14():1128641. PubMed ID: 36936969
[TBL] [Abstract][Full Text] [Related]
12. T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.
Ettinger RA; Paz P; James EA; Gunasekera D; Aswad F; Thompson AR; Matthews DC; Pratt KP
Blood; 2016 Oct; 128(16):2043-2054. PubMed ID: 27471234
[TBL] [Abstract][Full Text] [Related]
13. Hunting down factor VIII in the immunopeptidome.
Hartholt RB; Peyron I; Voorberg J
Cell Immunol; 2016 Mar; 301():59-64. PubMed ID: 26610639
[TBL] [Abstract][Full Text] [Related]
14. B-cell and T-cell epitopes in anti-factor VIII immune responses.
Pratt KP; Thompson AR
Clin Rev Allergy Immunol; 2009 Oct; 37(2):80-95. PubMed ID: 19184559
[TBL] [Abstract][Full Text] [Related]
15. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.
Steinitz KN; van Helden PM; Binder B; Wraith DC; Unterthurner S; Hermann C; Schuster M; Ahmad RU; Weiller M; Lubich C; de la Rosa M; Schwarz HP; Reipert BM
Blood; 2012 Apr; 119(17):4073-82. PubMed ID: 22394599
[TBL] [Abstract][Full Text] [Related]
16. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
17. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients.
Hu G; Guo D; Key NS; Conti-Fine BM
Thromb Haemost; 2007 May; 97(5):788-94. PubMed ID: 17479189
[TBL] [Abstract][Full Text] [Related]
18. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.
Jacquemin M; Vantomme V; Buhot C; Lavend'homme R; Burny W; Demotte N; Chaux P; Peerlinck K; Vermylen J; Maillere B; van der Bruggen P; Saint-Remy JM
Blood; 2003 Feb; 101(4):1351-8. PubMed ID: 12393451
[TBL] [Abstract][Full Text] [Related]
20. Dangerous liaisons: how the immune system deals with factor VIII.
Wroblewska A; Reipert BM; Pratt KP; Voorberg J
J Thromb Haemost; 2013 Jan; 11(1):47-55. PubMed ID: 23140211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
